VGI Health Technology (XNEC:VTL) Short-Term Capital Lease Obligation : A$0.00 Mil (As of . 20)

View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Short-Term Capital Lease Obligation?

VGI Health Technology's Short-Term Capital Lease Obligation for the quarter that ended in . 20 was A$0.00 Mil.

VGI Health Technology Short-Term Capital Lease Obligation Historical Data

The historical data trend for VGI Health Technology's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Short-Term Capital Lease Obligation Chart

VGI Health Technology Annual Data

Trend

Short-Term Capital Lease Obligation

VGI Health Technology Semi-Annual Data

Short-Term Capital Lease Obligation

VGI Health Technology Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

VGI Health Technology Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

VGI Health Technology (XNEC:VTL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003

Website

https://www.vgiht.com

VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines